- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: 90Y-DOTA-hLL2 | 90Y-epratuzumab tetraxetan | 90Y-hLL2 | AMG-412 | IMMU-hLL2 | LymphoCide® (proposed proprietary name)
Compound class: Antibody
Comment: Epratuzumab is a humanized monoclonal antibody. It is derived from the murine IG2a monoclonal antibody, LL2 (EPB-2). Epratuzumab has antineoplastic and antiinflammatory actions .
The antibody can be conjugated with tetraxetan (DOTA) which allows chelation of radionucleotides such as yttrium-90 .
|No information available.|
|Summary of Clinical Use|
|Epratuzumab is an investigational immunotherapy in Phase 3 clinical trial for the treatment of systemic lupus erythematosus (SLE; failure to show efficacy reported in ) , relapsed acute lymphoblastic leukemia (ALL) and relapsed/refractory, aggressive non-Hodgkin's lymphoma (NHL). Click here to link to ClinicalTrials.gov's full listing of registered epratuzumab trials.|
|Mechanism Of Action and Pharmacodynamic Effects|
|Epratuzumab binds to the CD22 glycoprotein on the surface of mature and malignant B-cells and appears to stimulate antibody-dependent cellular cytotoxicity (ADCC) as its main anti-tumour mechanism [2,4].|